Skip to main content

Bio-Rad Laboratories, Inc. (BIO) Stock Analysis

Buy WaitModerate Confidence

Healthcare · Medical Devices

Earnings in 0 days (2026-04-30). Expect elevated volatility around the report — consider waiting for post-earnings price action before new entries.

Wait for pullback to $265.02. Weak momentum — blocks BUY_NOW at $277.17. Engine's entry $265.02 (Support Atr Sticky) is the shallowest technical level that clears the 2:1 A.R:R minimum. Key risks: Cyclical risk: PE expanding 2.5x (earnings normalizing); Analyst target reached - limited upside remaining.

Bio-Rad Laboratories develops and markets instruments, reagents, and consumables for life science research (40% of 2025 net sales) and clinical diagnostics (60%), operating directly in 36+ countries. ~60% of sales are international with Europe as the largest region; the company... Read more

$277.17+11.3% A.UpsideScore 4.8/10#36 of 40 Medical Devices
Entry $265.02(Support Atr Sticky)Stop $244.77Target $306.59(resistance)A.R:R -1.0:1Setup A.R:R 2.4:1
Analyst target$302.50+9.1%4 analysts
$306.59our TP
$277.17price
$302.50mean
$320

Wait for pullback to $265.02. Weak momentum — blocks BUY_NOW at $277.17. Engine's entry $265.02 (Support Atr Sticky) is the shallowest technical level that clears the 2:1 A.R:R minimum. Key risks: Cyclical risk: PE expanding 2.5x (earnings normalizing); Analyst target reached - limited upside remaining. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Earnings in 0 days. Wait until post-earnings. Score 4.8/10, moderate confidence.

Passes 3/6 gates (clean insider activity, no SEC red flags, semi cycle peak clear). Fails on weak momentum and favorable risk/reward ratio and earnings proximity 0d<=7d. Suitability: moderate.

Val5.3Qual5.4Grw3.5Mom1.9Sent5.4Ins5.0Peer4.2Tech6.8Risk6.24.8OVERALL

Thesis

Rewards
No bull case signals
Risks
Cyclical risk: PE expanding 2.5x (earnings normalizing)
Analyst target reached - limited upside remaining

Key Metrics

P/E (TTM)9.9
P/E (Fwd)24.2
Mkt Cap$7.4B
EV/EBITDA16.8
Profit Mgn29.4%
ROE10.8%
Rev Growth3.9%
Beta1.16
DividendNone
Rating analysts10

Quality Signals

Piotroski F8/9

Options Flow

P/C0.50bullish
IV73%elevated
Max Pain$180-35.1% vs spot

Material Events(8-K, last 90d)

  • 2026-04-24Item 5.02LOW
    Stockholders approved the Amended 2017 Incentive Award Plan at the April 21, 2026 annual meeting, adding 335,000 shares and extending expiration to March 18, 2036. Routine compensatory arrangement.
    SEC filing →

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer

Rating Breakdown

2 floor-breakers

Price action weak — below key moving averages, no momentum carry. Needs a base before trend-continuation setups apply.static

Macd
0.0
Obv
1.0
Volume
1.7
Ma Position
2.2
Rsi
4.5
Volume distribution (falling OBV)Below 200-MA but MA still rising (+2.3%/30d) — pullback in uptrend, not confirmed weakness

Growth below the gate floor. Component breakdown shows what dragged the score down.static

Revenue Growth
3.5
Low model confidence on this dimension (33%).
GatesMomentum 1.9<4.5A.R:R -1.0=NEGATIVEEARNINGS PROXIMITY 0d<=7dInsider activity: OKNo SEC red flagsSEMI CYCLE PEAK CLEARSuitability: Moderate
RSI
49 · Neutral
↓ 20D MA↓ 50D MA↓ 200D MADEATH CROSSSupport $270.37Resistance $312.85

Price Targets

$245
$265
$307
A.Upside+10.6%
A.R:R-1.0:1
Setup A.R:R (at entry)2.4:1

Position Sizing

ConvictionNone
Suggested %0.5%
Max %1%
RegimeCautious

Risk Alerts

! Target reached (-7.3% upside)
! Earnings in 0 days - binary event risk
! Momentum score 1.9/10 — below 4.5 minimum

Earnings

B
B
B
M
3/4 beats
Next Earnings2026-04-30 (0d)

Verdict History

reverse chrono — latest first
Loading history...
Verdicts are recorded on every nightly pipeline run. Rows capture transitions (verdict flips, score deltas ≥0.3, entry/TP/SL changes). Rows with a ▶ can be expanded to see the change reason. Aggregate cohort performance is tracked in the recommendation ledger.
Frequently Asked Questions
Is BIO stock a buy right now?

Wait for pullback to $265.02. Weak momentum — blocks BUY_NOW at $277.17. Engine's entry $265.02 (Support Atr Sticky) is the shallowest technical level that clears the 2:1 A.R:R minimum. Key risks: Cyclical risk: PE expanding 2.5x (earnings normalizing); Analyst target reached - limited upside remaining. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Earnings in 0 days. Wait until post-earnings. Target $306.59 (+10.6%), stop $244.77 (−13.2%), Setup A.R:R 2.4:1. Score 4.8/10, moderate confidence.

What is the BIO stock price target?

Take-profit target: $306.59 (+11.3% upside). Target $306.59 (+10.6%), stop $244.77 (−13.2%), Setup A.R:R 2.4:1. Stop-loss: $244.77.

What are the risks of investing in BIO?

Cyclical risk: PE expanding 2.5x (earnings normalizing); Analyst target reached - limited upside remaining.

Is BIO overvalued or undervalued?

Bio-Rad Laboratories, Inc. trades at a P/E of 9.9 (forward 24.2). TrendMatrix value score: 5.3/10. Verdict: Buy (Wait for Entry).

What do analysts say about BIO?

10 analysts cover BIO with a consensus score of 3.8/5. Average price target: $303.

What does Bio-Rad Laboratories, Inc. do?Bio-Rad Laboratories develops and markets instruments, reagents, and consumables for life science research (40% of 2025...

Bio-Rad Laboratories develops and markets instruments, reagents, and consumables for life science research (40% of 2025 net sales) and clinical diagnostics (60%), operating directly in 36+ countries. ~60% of sales are international with Europe as the largest region; the company also holds a $5.7B fair-value equity stake in Sartorius AG (38% of ordinary shares).

Related stocks: GMED (Globus Medical, Inc.) · TMDX (TransMedics Group, Inc.) · DXCM (DexCom, Inc.) · INSP (Inspire Medical Systems, Inc.) · HAE (Haemonetics Corporation)